The overarching goal of the Oregon ADC (OADC) is twofold: (1) to focus on early detection of change in order to define mechanisms supporting healthy brain aging and the transition to MCI and early dementia, and (2) to facilitate developing effective therapies to prevent or limit these transitions. To achieve these objectives, six cores are organized to catalyze and sustain innovative research and discovery in Alzheimer Disease (AD) and related disorders through an organizational infrastructure that supports a rich collaborative environment composed of leading edge technologies and methods, multi-disciplinary scientists, empowered research volunteers, and an inspired community of lay and professional stakeholders. The OADC provides the necessary materials to support research through well-characterized research participants, biological specimens, brain tissue, data provision and analytics. The OADC focuses on specific areas of emphasis: (1) Preclinical dementia and activity of disease emphasizing the oldest old; (2) Markers of meaningful change captured through studies of peripheral biomarkers, neuroimaging and continuous in-home behavioral monitoring; (3) Neuropathology of brain aging and late life dementia; (4) Novel testing of novel treatments; and (5) Improving education and sharing knowledge about dementia. To attain these goals and objectives, the OADC Specific Aims are to: 1. Catalyze and sustain innovative research and discovery in AD and related disorders through an organizational infrastructure supporting a rich collaborative environment composed of leading edge technologies and methods, multi-disciplinary scientists, empowered research volunteers, and an inspired community of lay and professional stakeholders. 2. Focus the innovation and discovery infrastructure of the center toward specific areas of emphasis: (1) Preclinical dementia and activity of disease emphasizing the oldest old; (2) Markers of meaningful change captured through studies of peripheral biomarkers, neuroimaging and continuous in-home behavioral monitoring; (3) Neuropathology of brain aging and late life dementia; (4) Novel testing of novel treatments; and (5) Improving education and knowledge about dementia. 3. Provide the necessary materials to support the science through well-characterized research participants, biological specimens, brain tissue, data provision and analytics. 4. Contribute to the national research commons relevant to AD and related disorders. 5. Provide venues and mechanisms for education and training of new scientists, as well as educating and informing key stakeholders such as clinicians, patients and diverse family members to address the challenges of dementia.

Public Health Relevance

Overall The Oregon Alzheimer's Disease Center infrastructure creates a unique environment for research and discovery of new insights into healthy brain aging, transitions to Alzheimer's, and for treatment and management of cognitive decline. This is facilitated by state-of the art clinical, biochemical, technological and statisticl tools, subject and tissue resources, and data widely shared for maximum impact with the scientific community and appropriately translated to families and other key stakeholders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
2P30AG008017-26
Application #
8848722
Study Section
Special Emphasis Panel (ZAG1-ZIJ-7 (J1))
Program Officer
Silverberg, Nina B
Project Start
1997-01-01
Project End
2020-03-31
Budget Start
2015-04-15
Budget End
2016-03-31
Support Year
26
Fiscal Year
2015
Total Cost
$1,540,000
Indirect Cost
$540,000
Name
Oregon Health and Science University
Department
Neurology
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Brenowitz, Willa D; Han, Fang; Kukull, Walter A et al. (2018) Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. Neurobiol Aging 62:64-71
Seelye, Adriana; Mattek, Nora; Sharma, Nicole et al. (2018) Weekly observations of online survey metadata obtained through home computer use allow for detection of changes in everyday cognition before transition to mild cognitive impairment. Alzheimers Dement 14:187-194
Nguyen, Madeline T; Mattek, Nora; Woltjer, Randy et al. (2018) Pathologies Underlying Longitudinal Cognitive Decline in the Oldest Old. Alzheimer Dis Assoc Disord 32:265-269
Goodman, James R; Adham, Zachariah O; Woltjer, Randall L et al. (2018) Characterization of dural sinus-associated lymphatic vasculature in human Alzheimer's dementia subjects. Brain Behav Immun 73:34-40
Gallagher, Damien; Kiss, Alex; Lanctot, Krista L et al. (2018) Toward Prevention of Mild Cognitive Impairment in Older Adults With Depression: An Observational Study of Potentially Modifiable Risk Factors. J Clin Psychiatry 80:
Lindauer, A; Croff, R; Mincks, K et al. (2018) ""It Took the Stress out of Getting Help"": The STAR-C-Telemedicine Mixed Methods Pilot. Care Wkly 2:7-14
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Simon, Matthew J; Wang, Marie X; Murchison, Charles F et al. (2018) Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. Sci Rep 8:12389
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211

Showing the most recent 10 out of 482 publications